NEWS HOME

»

COVAXIN

 

Nine research studies published on Covaxin's safety in a year: Bharat Biotech

Aimed at demonstrating data generation and data transparency, Covaxin maker Bharat Biotech on Saturday said that the company has published nine research studies on the safety and efficacy of its vaccine in a year.... read..

---

 

Bharat Biotech shares full data of all research studies of Covaxin

Bharat Biotech on Saturday shared full data of all research studies of its Covaxin-- India's first indigenous COVID-19 vaccine.... read..

---

 

Bharat Biotech's US partner, Ocugen to apply for full approval for Covaxin

Bharat Biotech's US partner Ocugen Inc said that the company will no longer pursue an Emergency Use Authorization (EUA) for COVAXIN and the US Food and Drug Administration (FDA) has recommended that the company go for the Biologics Licence Application (BL... read..

---

 

US FDA denies emergency use approval for Covaxin

The US Food and Drug administration has denied approval for emergency use of Covaxin, developed by Hyderabad-based Bharat Biotech, and has asked for additional data, biopharmaceutical Ocugen, the US partner of the Indian vaccine maker has said.... read..

---

 

Working for full US FDA approval of Covaxin: Bharat Biotech (Ld)

A day after the US Food and Drug administration (FDA) denied approval for emergency use of Covaxin, the Hyderabad-based Bharat Biotech on Friday said that it is following the recommendation for additional data and will work for full approval.... read..

---

 

With no EUA, Covaxin's launch in US may be delayed

With the US Food and Drug Administration (US FDA) recommending Ocugen Inc, the US partner of Bharat Biotech, to go for Biologics License Application (BLA) instead of Emergency Use Authorisation (EUA), the launch of the first indigenous Indian Covid-19 vac... read..

---

 

No EUA delays US launch, Covaxin maker working for full approval (2nd Lead)

A day after the US Food and Drug administration (FDA) denied approval for emergency use of Covaxin, the Hyderabad-based Bharat Biotech on Friday said that it is following the recommendation for additional data and will work for full approval.... read..

---

 

We respect US FDA decision, but it won't impact India's vaccine plan: Centre on Covaxin EUA rejection

Reacting to the United States Food and Drug Administration (FDA)'s rejection of Bharat Biotech's Covaxin jab for emergency use authorization, the Union Health Ministry on Friday said that it respects the decision taken by the authority but it will not hav... read..

---

 

Covaxin's Phase 3 trials results likely next month

The results of third phase trials of India's first indigenously developed Covid-19 vaccine Covaxin are expected to be released next month.... read..

---

 

People struggling, travelling long distances to get COVAXIN dose

As people are struggling to book slots for COVID-19 vaccination in their cities, many of them who are in less than 45 years age group from Delhi-NCR are travelling a long distance to get their first and even second dose of COVAXIN.... read..

---

 

COVAXIN phase 3 full trial data will be made public in July: Bharat Biotech

Hyderabad-based vaccine manufacturer Bharat Biotech, which is carrying out its phase 3 trial will publish the data in July following that the company will be applying for the full licensure of COVAXIN.... read..

---

 

Govt caps charges of COVID vaccines in pvt hospitals; Covishield to cost Rs 780, Covaxin Rs 1,410, Sputnik V Rs 1,145

As part of the revised COVID-19 vaccine policy, the Centre on Tuesday issued an order capping the prices for administration of three approved coronavirus vaccines in private hospitals across the country.... read..

---

 

Centre places orders for 25 crore doses of Covishield, 19 crore Covaxin doses

The Union Health Ministry on Tuesday informed that the Centre has placed an order to purchase 25 crores doses of Covishield and 19 crore doses of Covaxin.... read..

---

 

Delhi gets Covaxin stock for 18-44, to use it for 2nd dose

The Delhi government has received 40,000 doses of Covaxin from the Centre for the 18-44 age group, but this will be administered only as the second dose, AAP lawmaker Atishi said on Monday.... read..

---

 

Priority given to those who need second dose of Covaxin: Delhi govt to HC

The Delhi government on Monday informed the Delhi High Court that it has directed that all private hospitals and nursing homes functioning as COVID vaccination centres to ensure that the Covaxin will be used to vaccinate only those people (of age group 18... read..

---

 

Seropositivity rate, anti-spike antibody titre higher in Covishield than Covaxin: Study

A latest study has found that both vaccines, Covishield and Covaxin elicited good immune response after two doses, although seropositivity rates and median anti-spike antibody titre was significantly higher in Covishield as compared to Covaxin.... read..

---

 

Delhi govt orders pvt hospitals, nursing homes to administer Covaxin jabs only to second-dose beneficiaries from 18-44 age group

The Delhi government on Sunday ordered all private hospitals and nursing homes, functioning as COVID vaccination centres for Covaxin, to ensure that the doses are used only to vaccinate those people from 18-44 age group who are eligible for receiving the ... read..

---

 

AIIMS Delhi to start screening children for Covaxin trials from Monday

The All India Institute of Medical Sciences (AIIMS), Delhi, will start screening children for clinical trials of indigenous home-grown COVID-19 vaccine, Bharat Biotech's Covaxin, from Monday, sources said.... read..

---